Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi
Authors:
- Armando SantoroASArmando Santoro
- Michele SpinaMSMichele Spina
- Catello CalifanoCCCatello Califano
- Giorgina SpecchiaGSGiorgina Specchia
- Michele CarellaMCMichele Carella
- Ugo ConsoliUCUgo Consoli
- Francesca PalombiFPFrancesca Palombi
- Maurizio MussoMMMaurizio Musso
- Alessandro PulsoniAPAlessandro Pulsoni
- Sofya KovalchukSKSofya Kovalchuk
- Maurizio BonfichiMBMaurizio Bonfichi
- 30 July 2021
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (10) , 2547-2556
Abstract
We investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving > 85% of the programmed dose. The mean dose intensity in the overall patient population (n = 96) was 93.7%, and the median duration of dd-ABVD was 85 days (range, 14–115) versus an expected duration of 84 days. PET-2 was available for 92/96 (95.8%) patients, of whom 79 were PET-2 negative (85.9%). In total, 90 (93.8%) patients showed complete response at the end of treatment. With a follow-up of 80.9 months (3.3–103.2), the median progression-free survival (PFS) and overall survival (OS) were not reached. At 84 months, PFS and OS rates were 88.4% and 95.7%, respectively. No evidence for a difference in PFS or OS was observed for PET-2-negative and PET-2-positive patients. Infections were documented in 8.3% and febrile neutropenia in 6.2% of cases. Four patients died: one had alveolitis at cycle 3, one death was unrelated to treatment, and two died from a secondary cancer. dd-ABVD is feasible and demonstrates activity in early-stage unfavorable HL. The predictive role of PET-2 positivity in early-stage unfavorable HL remains controversial. The study was registered in the EudraCT (reference number, 2011–003,191-36) and the ClinicalTrials.gov (reference number, NCT02247869) databases.Keywords
This publication has 25 references indexed in Scilit:
- A phase II study of dose‐dense and dose‐intense ABVD (ABVDDD‐DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphomaBritish Journal of Haematology, 2014
- Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitionsAnnals of Oncology, 2013
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 TrialJournal of Clinical Oncology, 2012
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 TrialJournal of Clinical Oncology, 2010
- 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin LymphomaJournal of Nuclear Medicine, 2010
- Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's DiseaseNew England Journal of Medicine, 2007
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaBlood, 2006
- Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study GroupJournal of Clinical Oncology, 2003
- Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's diseaseAnnals of Oncology, 1996